Printer Friendly

BIOCHEM PHARMA WITHDRAWS INTERNATIONAL EQUITY OFFERING

 BIOCHEM PHARMA WITHDRAWS INTERNATIONAL EQUITY OFFERING
 LAVAL, Quebec, June 8 /PRNewswire/ -- BioChem Pharma Inc.


("BioChem") (NASDAQ: BCHXF) announced today that, due to the fall in its share price in recent weeks, it has decided not to proceed with its combined international offering of 3,500,000 new common shares.
 BioChem confirms that there have been no adverse changes in its business that would explain the decline in its share price. To the contrary, the Phase I/II clinical trails on the company's anti-AIDS compound 3TC, which are being conducted by Glaxo, are progressing well with preliminary information from such trails to be presented at the International AIDS Conference in Amsterdam next month.
 The company's financial position remains strong with net cash exceeding $30 million. This position is expected to be further enhanced by new capital from warrant, option and equity subscriptions amounting in aggregate to approximately $40 million during the rest of the current financial year to Jan. 31, 1993.
 BioChem was pleased by the quality and quantity of demand in the UK and Continental Europe where it received indications of interest significantly in excess of the targeted amount of 1,750,000 new common shares.
 The company is committed to proceed with a full listing on the London Stock Exchange later in the year. In view of their success in the UK and Continental Europe, Kleinwort Benson have been appointed global financial adviser to BioChem Pharma.
 BioChem Pharma Inc. is a pharmaceutical company dedicated to research, development and commercialization of innovative products for the detection, prevention and treatment of human diseases. The company's common shares are traded on the Montreal and Toronto stock exchanges (BCH) and on the NASDAQ exchange (BCHXF).
 -0- 6/8/92
 /CONTACT: Francesco Bellini, president and chief executive officer of BioChem Pharma, 514-681-1744; Gordon Duncan, director of Kleinwort Benson, 011-44-71-623-8000; or Luc Beauregard or Michele Roy of National Public Relations Inc., 514-843-7171, for BioChem/
 (BCHXF) CO: BioChem Pharma Inc. ST: Quebec IN: MTC SU: OFR


TQ-SM -- NY030 -- 7841 06/08/92 10:59 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 8, 1992
Words:339
Previous Article:TRANZONIC DECLARES DIVIDENDS ON COMMON AND CLASS B COMMON
Next Article:ENEX RESOURCES REPURCHASES 16 PERCENT OF ITS OUTSTANDING COMMON STOCK
Topics:


Related Articles
IAF BIOCHEM INTERNATIONAL BECOMES BIOCHEM PHARMA
3TC ACTIVE AGAINST HEPATITIS B VIRUS
STRATEGIC RESEARCH COLLABORATION BETWEEN BIOCHEM PHARMA AND THE BIOTECHNOLOGY RESEARCH INSTITUTE IN THE AREA OF CARDIOVASCULAR DISEASES
BIOCHEM PHARMA PRESIDENT TO COMMENT ON RESULTS OF PHASE I/II TESTS ON 3TC
GLAXO DOUBLES IT'S PARTICIPATION IN BIOCHEM PHARMA INC.
1992-1993 FISCAL YEAR: BIOCHEM PHARMA MAINTAINS SOLID FINANCIAL POSITION
BIOCHEM IS STILL GROWING
BIOCHEM IS STILL GROWING
NORTH AMERICAN VACCINE ANNOUNCES WITHDRAWAL OF REGISTRATION STATEMENT
ONCOGENE SCIENCE, INC. ANNOUNCES SALE OF 500,000 SHARES OF COMMON STOCK TO BIOCHEM PHARMA INC.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters